rs12232375 — ZFPM1 ZFPM1 Hematology/Cardiac Locus Variant

Intronic ZFPM1 variant tagging reduced GATA cofactor regulatory activity; the C allele associates with lower mean corpuscular hemoglobin, altered plateletcrit, elevated reticulocyte count, and minor PR interval prolongation

See your personal result for ZFPM1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ZFPM1 — When a Heart and Blood Gene Shapes Your Red Cell Profile

Deep in chromosome 16, a single gene quietly coordinates two of the body's most vital systems: blood cell production and cardiac structure. ZFPM1 encodes FOG1 (Friend of GATA 1)11 FOG1 (Friend of GATA 1)
a transcriptional cofactor that partners with GATA transcription factors to drive erythroid and megakaryocyte differentiation. Without functional FOG1, developing red blood cells stall at the proerythroblast stage and fail to mature, while megakaryocytes — the precursors of platelets — also depend on FOG1 for normal differentiation. In the heart, FOG1 cooperates with GATA-4/5/6 transcription factors to shape the outlet tract and atrioventricular valves; mice conditionally lacking endothelial FOG1 develop double outlet right ventricle and valve malformations and die at embryonic day 14.5.

The rs12232375 variant sits within intron 2 of ZFPM1 at chromosome 16q24.2, approximately 10,850 bases from the nearest exon boundary (NM_153813.3:c.268+10850G>C). It is a regulatory tag SNP — not a protein-altering change itself, but a marker for a haplotype block that modulates ZFPM1 expression or splicing in hematopoietic and cardiac progenitor cells.

The Mechanism

FOG1 operates as both a co-activator and co-repressor, depending on the GATA partner it joins. In erythroid progenitors it co-activates GATA-1 target genes required for hemoglobin synthesis, including globin chain genes and heme biosynthesis enzymes. The pathway to nuclear localization is regulated: PI3K phosphorylates HSCB, which degrades the cytoplasmic anchor TACC3, freeing FOG1 to enter the nucleus and activate differentiation programs. When FOG1 is insufficiently active, cells accumulate in early progenitor stages, and mature erythrocytes emerging from the marrow carry less hemoglobin per cell22 less hemoglobin per cell
a lower MCH reflects smaller or less hemoglobin-dense red blood cells.

A secondary effect of reduced FOG1 activity is cholesterol dysregulation in developing erythroid cells: FOG1 normally represses the cholesterol transporters ABCA1 and LDLR during differentiation. Reduced FOG1 function allows excess cholesterol accumulation and increased membrane fluidity in the erythroid lineage, potentially compounding the hemoglobin-loading defect.

The same locus also tags variants affecting platelet biology: nearby LD partners (rs28634651, rs17175830) associate with plateletcrit and platelet count at genome-wide significance. In the cardiovascular system, ZFPM1's developmental role in endothelial-derived cardiac tissue appears to persist as a subtle influence on cardiac conduction — the locus associates with PR interval prolongation in a large multi-ancestry GWAS of electrocardiographic traits.

The Evidence

The strongest direct evidence comes from Vuckovic et al., Cell 202033 Vuckovic et al., Cell 2020
"The Polygenic and Monogenic Basis of Blood Traits and Diseases," 746,667 individuals, which identified rs12232375 as genome-wide significant for mean corpuscular hemoglobin (MCH, p = 7×10⁻²², beta = −0.072 SD), reticulocyte count, and plateletcrit. The effect on MCH — while modest in absolute terms — positions ZFPM1 alongside established erythropoietic regulators in an unbiased, replicated multi-population study.

The complementary trans-ethnic study Chen et al., Cell 202044 Chen et al., Cell 2020
746,667 individuals from 5 global populations confirmed the locus for platelet traits; LD partners near ZFPM1 showed one of the strongest platelet count signals (p = 1×10⁻⁵⁰) in the dataset, underscoring the gene's dual role in both red cell and megakaryocyte lineages.

Cardiac relevance was established by Ntalla et al., Nat Commun 202055 Ntalla et al., Nat Commun 2020
202 PR interval loci, multi-ancestry, which identified an LD partner at the ZFPM1 locus as significantly associated with PR interval duration (p = 2×10⁻¹²) — consistent with FOG1's documented requirement for proper cardiac morphogenesis Katz et al., PNAS 200366 Katz et al., PNAS 2003.

Separately, a meta-analysis of circulating VEGF levels found a genome-wide significant signal at 16q24.2 (rs4782371; p = 1.59×10⁻⁹), implicating ZFPM1-region variants in vascular endothelial signaling77 vascular endothelial signaling
VEGF is critical for angiogenesis and vascular remodeling; reduced VEGF is associated with impaired wound healing and cardiovascular reserve.

Practical Actions

For most C-allele carriers, the MCH reduction is subclinical under normal dietary conditions; mean corpuscular hemoglobin typically stays within the normal reference range (27–33 pg) unless compounded by iron deficiency, vitamin B12 deficiency, or thalassemia trait. The actionable implications are:

Iron management: Lower MCH can be an early sign of iron-restricted erythropoiesis. C-allele carriers benefit from confirming their ferritin and serum iron are in the high-normal range, since ZFPM1-related MCH reduction will amplify any iron shortage. If MCH drifts below 27 pg, iron status should be evaluated before concluding the cause is genetic alone.

Cardiac monitoring: The PR interval association is subtle and clinical significance in heterozygotes is uncertain, but combined with other cardiac risk factors it adds incremental evidence for periodic ECG monitoring — especially relevant if the PR interval is already at the high-normal boundary (>160 ms).

Red cell indices context: Understanding that your lower-normal MCH has a partial genetic explanation prevents unnecessary clinical workups for iron deficiency when MCH is marginally low but ferritin is normal.

Interactions

ZFPM1 acts directly downstream of GATA-1/GATA-2 transcription factors. Variants in GATA1 (X-linked), GATA2, and their target genes interact with FOG1 activity. Rs28634651 (ZFPM1 locus, plateletcrit/PR interval) and rs17175830 (ZFPM1 locus, platelet count) are in partial LD with rs12232375 and collectively represent the haplotype block's effects on the erythroid- megakaryocyte-cardiac axis.

In patients with concurrent iron deficiency, the genetically-lower MCH from ZFPM1 variants and the nutritionally-lower MCH from reduced iron stores are additive — serum ferritin should be checked before attributing low MCH entirely to this variant.

Nutrient Interactions

iron altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

Your ZFPM1 genotype shows the common pattern — standard hemoglobin content per red blood cell

You carry two copies of the G reference allele at rs12232375, the most common genotype found in about 95% of people globally. Your ZFPM1 gene is expected to produce FOG1 at typical expression levels in erythroid and cardiac progenitor cells, supporting normal red cell hemoglobin loading and standard blood cell parameters. No specific action is needed based on this genotype.

CG Reduced MCH Tendency Intermediate

One copy of the ZFPM1 C allele — mild tendency toward lower mean corpuscular hemoglobin

ZFPM1 encodes FOG1, a transcriptional cofactor that partners with GATA-1 to drive erythroid maturation, hemoglobin gene expression, and heme biosynthesis. The rs12232375 C allele tags a regulatory haplotype in intron 2 that likely reduces FOG1 availability in erythroid progenitors, leading to slightly less complete hemoglobin loading as red cells mature. The genetic contribution is real but modest; clinical significance depends on baseline iron and B12 status and the presence of other hemoglobin-related variants.

The ZFPM1 locus also influences platelet biology via the shared erythroid-megakaryocyte progenitor pool where FOG1 is required for both lineages. The PR interval association (rs28634651 LD partner, p = 2×10⁻¹²) is consistent with FOG1's established role in cardiac endothelial development but has no established clinical guideline at the variant level in heterozygotes.

CC Low MCH Tendency Decreased

Two copies of the ZFPM1 C allele — increased tendency toward lower mean corpuscular hemoglobin and altered blood cell indices

ZFPM1 encodes FOG1, which must translocate to the nucleus of erythroid progenitors to activate hemoglobin-related genes and repress cholesterol transporter genes (ABCA1, LDLR) during maturation. Homozygous CC carriers have the highest burden of ZFPM1 regulatory variation at this locus, potentially impairing FOG1 activity in both erythroid and megakaryocyte lineages. The ZFPM1 locus also influences plateletcrit (p = 6×10⁻²¹ for a nearby LD partner), reticulocyte count, and circulating VEGF levels, suggesting effects on multiple vascular and hematopoietic pathways.

The cardiac-conduction PR interval association for the ZFPM1 locus (p = 2×10⁻¹² for an LD partner) is noteworthy for CC homozygotes: while this finding does not indicate a diagnosed arrhythmia risk, it warrants baseline ECG documentation for future reference, particularly if combined with other cardiac risk factors.